105 related articles for article (PubMed ID: 7884439)
1. Combination chemotherapy of metastatic melanoma.
Berd D; Mastrangelo MJ
J Clin Oncol; 1995 Mar; 13(3):796-7. PubMed ID: 7884439
[No Abstract] [Full Text] [Related]
2. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Del Prete SA; Maurer LH; O'Donnell J; Forcier RJ; LeMarbre P
Cancer Treat Rep; 1984 Nov; 68(11):1403-5. PubMed ID: 6541973
[No Abstract] [Full Text] [Related]
3. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Lattanzi SC; Tosteson T; Chertoff J; Maurer LH; O'Donnell J; LeMarbre PJ; Mott L; DelPrete SA; Forcier RJ; Ernstoff MS
Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728
[TBL] [Abstract][Full Text] [Related]
6. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
9. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
10. The Dartmouth Regimen: gone or going strong?
McClay EF; Berd D; Mastrangelo MJ
Cancer Invest; 1998; 16(6):421-3. PubMed ID: 9679534
[No Abstract] [Full Text] [Related]
11. Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Stein ME; Bernstein Z; Drumea K; Zalik M; Shklar Z; Steiner M; Haim N
Am J Clin Oncol; 1999 Feb; 22(1):62-4. PubMed ID: 10025383
[TBL] [Abstract][Full Text] [Related]
12. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
13. Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
Cohen SM; Ohnuma T; Cheung T; Holland JF
Cancer Treat Rep; 1983 Oct; 67(10):947-8. PubMed ID: 6194881
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408
[TBL] [Abstract][Full Text] [Related]
15. Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma.
Chmielowska E; Potemski P; Pluzańska A
J Clin Oncol; 1995 Aug; 13(8):2146-7. PubMed ID: 7636562
[No Abstract] [Full Text] [Related]
16. Malignant melanoma: primary presentation in bone marrow and lymph node.
Basile M; Moskowitz B; Harris J; Blumberg N; Bennett JM
Med Pediatr Oncol; 1992; 20(1):75-7. PubMed ID: 1727216
[TBL] [Abstract][Full Text] [Related]
17. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
McClay EF; McClay ME
J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Wojtukiewicz MZ; Kozlowski L; Ostrowska K; Dmitruk A; Zacharski LR
Thromb Haemost; 2003 Feb; 89(2):405-7. PubMed ID: 12574822
[No Abstract] [Full Text] [Related]
20. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
